Annual CFF
-$6.57 B
+$256.00 M+3.75%
31 December 2023
Summary:
AstraZeneca annual cash flow from financing activities is currently -$6.57 billion, with the most recent change of +$256.00 million (+3.75%) on 31 December 2023. During the last 3 years, it has fallen by -$4.36 billion (-198.09%). AZN annual CFF is now -208.53% below its all-time high of $6.05 billion, reached on 31 December 2007.AZN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$4.13 B
-$2.91 B-238.05%
30 September 2024
Summary:
AstraZeneca quarterly cash flow from financing activities is currently -$4.13 billion, with the most recent change of -$2.91 billion (-238.05%) on 30 September 2024. Over the past year, it has dropped by -$1.41 billion (-51.54%). AZN quarterly CFF is now -133.85% below its all-time high of $12.21 billion, reached on 30 June 2007.AZN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$3.62 B
-$1.41 B-63.55%
30 September 2024
Summary:
AstraZeneca TTM cash flow from financing activities is currently -$3.62 billion, with the most recent change of -$1.41 billion (-63.55%) on 30 September 2024. Over the past year, it has increased by +$3.02 billion (+45.49%). AZN TTM CFF is now -154.00% below its all-time high of $6.70 billion, reached on 31 March 2008.AZN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.8% | -51.5% | +45.5% |
| 3 y3 years | -198.1% | -3009.2% | -245.2% |
| 5 y5 years | -221.3% | -52.3% | -3.2% |
AZN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -280.0% | +3.8% | -303.7% | at low | -199.1% | +51.9% |
| 5 y | 5 years | -280.0% | +3.8% | -156.7% | at low | -199.1% | +51.9% |
| alltime | all time | -208.5% | +29.6% | -133.8% | at low | -154.0% | +61.8% |
AstraZeneca Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.13 B(+238.1%) | -$3.62 B(+63.5%) |
| June 2024 | - | -$1.22 B(-160.3%) | -$2.21 B(-11.8%) |
| Mar 2024 | - | $2.03 B(-796.9%) | -$2.51 B(-61.8%) |
| Dec 2023 | -$6.57 B(-3.8%) | -$291.00 M(-89.3%) | -$6.57 B(-1.0%) |
| Sept 2023 | - | -$2.73 B(+79.5%) | -$6.63 B(+24.3%) |
| June 2023 | - | -$1.52 B(-25.2%) | -$5.34 B(+4.4%) |
| Mar 2023 | - | -$2.03 B(+467.3%) | -$5.11 B(-25.0%) |
| Dec 2022 | -$6.82 B(-287.0%) | -$358.00 M(-75.0%) | -$6.82 B(-9.2%) |
| Sept 2022 | - | -$1.43 B(+10.4%) | -$7.52 B(+26.4%) |
| June 2022 | - | -$1.29 B(-65.4%) | -$5.94 B(-325.2%) |
| Mar 2022 | - | -$3.74 B(+255.9%) | $2.64 B(-27.7%) |
| Dec 2021 | $3.65 B(-265.6%) | -$1.05 B(-840.1%) | $3.65 B(+46.5%) |
| Sept 2021 | - | $142.00 M(-98.1%) | $2.49 B(-30.7%) |
| June 2021 | - | $7.29 B(-366.9%) | $3.59 B(-239.6%) |
| Mar 2021 | - | -$2.73 B(+23.6%) | -$2.57 B(+16.7%) |
| Dec 2020 | -$2.20 B(+24.8%) | -$2.21 B(-277.8%) | -$2.20 B(<-9900.0%) |
| Sept 2020 | - | $1.24 B(+10.4%) | $13.00 M(-100.3%) |
| June 2020 | - | $1.13 B(-147.7%) | -$3.94 B(+15.0%) |
| Mar 2020 | - | -$2.36 B(<-9900.0%) | -$3.43 B(+94.3%) |
| Dec 2019 | -$1.76 B(-13.6%) | $6.00 M(-100.2%) | -$1.76 B(-49.6%) |
| Sept 2019 | - | -$2.71 B(-265.5%) | -$3.50 B(+463.2%) |
| June 2019 | - | $1.64 B(-334.8%) | -$622.00 M(-70.1%) |
| Mar 2019 | - | -$698.00 M(-59.7%) | -$2.08 B(+1.7%) |
| Dec 2018 | -$2.04 B(-30.4%) | -$1.73 B(-1124.9%) | -$2.04 B(+530.9%) |
| Sept 2018 | - | $169.00 M(-7.1%) | -$324.00 M(-90.9%) |
| June 2018 | - | $182.00 M(-127.5%) | -$3.56 B(+128.8%) |
| Mar 2018 | - | -$663.00 M(+5425.0%) | -$1.56 B(-47.0%) |
| Dec 2017 | -$2.94 B(+121.8%) | -$12.00 M(-99.6%) | -$2.94 B(-9.0%) |
| Sept 2017 | - | -$3.07 B(-240.3%) | -$3.23 B(+175.4%) |
| June 2017 | - | $2.19 B(-207.1%) | -$1.17 B(-41.5%) |
| Mar 2017 | - | -$2.04 B(+571.7%) | -$2.00 B(+51.4%) |
| Dec 2016 | -$1.32 B(-250.8%) | -$304.00 M(-70.0%) | -$1.32 B(-140.6%) |
| Sept 2016 | - | -$1.01 B(-174.8%) | $3.26 B(+0.1%) |
| June 2016 | - | $1.35 B(-199.6%) | $3.26 B(+56.3%) |
| Mar 2016 | - | -$1.36 B(-131.8%) | $2.09 B(+137.6%) |
| Dec 2015 | $878.00 M(-132.5%) | $4.28 B(-520.8%) | $878.00 M(-138.9%) |
| Sept 2015 | - | -$1.02 B(-662.4%) | -$2.25 B(-10.6%) |
| June 2015 | - | $181.00 M(-107.0%) | -$2.52 B(-17.6%) |
| Mar 2015 | - | -$2.57 B(-323.2%) | -$3.06 B(+13.2%) |
| Dec 2014 | -$2.71 B(-11.2%) | $1.15 B(-189.5%) | -$2.71 B(-26.0%) |
| Sept 2014 | - | -$1.29 B(+259.2%) | -$3.65 B(+5.0%) |
| June 2014 | - | -$358.00 M(-83.8%) | -$3.48 B(+15.0%) |
| Mar 2014 | - | -$2.21 B(-1200.5%) | -$3.03 B(-0.7%) |
| Dec 2013 | -$3.05 B(-38.1%) | $201.00 M(-118.1%) | -$3.05 B(-19.2%) |
| Sept 2013 | - | -$1.11 B(-1258.3%) | -$3.77 B(+30.0%) |
| June 2013 | - | $96.00 M(-104.3%) | -$2.90 B(-21.9%) |
| Mar 2013 | - | -$2.23 B(+325.1%) | -$3.72 B(-24.5%) |
| Dec 2012 | -$4.92 B(-47.2%) | -$525.00 M(+116.9%) | -$4.92 B(-19.0%) |
| Sept 2012 | - | -$242.00 M(-66.3%) | -$6.08 B(-30.0%) |
| June 2012 | - | -$718.00 M(-79.1%) | -$8.69 B(-3.0%) |
| Mar 2012 | - | -$3.44 B(+104.5%) | -$8.95 B(-4.0%) |
| Dec 2011 | -$9.32 B | -$1.68 B(-41.0%) | -$9.32 B(-1.5%) |
| Sept 2011 | - | -$2.85 B(+189.9%) | -$9.46 B(+13.4%) |
| June 2011 | - | -$983.00 M(-74.2%) | -$8.34 B(+6.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2011 | - | -$3.81 B(+109.2%) | -$7.80 B(+6.4%) |
| Dec 2010 | -$7.33 B(+102.1%) | -$1.82 B(+5.1%) | -$7.33 B(+34.6%) |
| Sept 2010 | - | -$1.73 B(+289.0%) | -$5.45 B(+5.0%) |
| June 2010 | - | -$445.00 M(-86.7%) | -$5.19 B(+10.1%) |
| Mar 2010 | - | -$3.34 B(-5315.6%) | -$4.71 B(+29.9%) |
| Dec 2009 | -$3.63 B(-43.0%) | $64.00 M(-104.4%) | -$3.63 B(-29.6%) |
| Sept 2009 | - | -$1.47 B(-4841.9%) | -$5.16 B(-14.5%) |
| June 2009 | - | $31.00 M(-101.4%) | -$6.03 B(-3.1%) |
| Mar 2009 | - | -$2.25 B(+54.1%) | -$6.22 B(-2.2%) |
| Dec 2008 | -$6.36 B(-205.1%) | -$1.46 B(-37.6%) | -$6.36 B(+24.9%) |
| Sept 2008 | - | -$2.35 B(+1374.8%) | -$5.09 B(-10.1%) |
| June 2008 | - | -$159.00 M(-93.4%) | -$5.67 B(-184.6%) |
| Mar 2008 | - | -$2.40 B(+1134.5%) | $6.70 B(+10.7%) |
| Dec 2007 | $6.05 B(-212.8%) | -$194.00 M(-93.4%) | $6.05 B(+18.9%) |
| Sept 2007 | - | -$2.92 B(-123.9%) | $5.09 B(-16.8%) |
| June 2007 | - | $12.21 B(-501.5%) | $6.12 B(-190.5%) |
| Mar 2007 | - | -$3.04 B(+163.4%) | -$6.76 B(+26.1%) |
| Dec 2006 | -$5.37 B(+17.4%) | -$1.15 B(-38.9%) | -$5.37 B(+8.1%) |
| Sept 2006 | - | -$1.89 B(+177.4%) | -$4.96 B(+6.1%) |
| June 2006 | - | -$681.00 M(-58.5%) | -$4.68 B(+0.6%) |
| Mar 2006 | - | -$1.64 B(+118.4%) | -$4.65 B(+1.7%) |
| Dec 2005 | -$4.57 B(+65.6%) | -$752.00 M(-53.1%) | -$4.57 B(+2.5%) |
| Sept 2005 | - | -$1.60 B(+144.7%) | -$4.46 B(+14.0%) |
| June 2005 | - | -$655.00 M(-58.1%) | -$3.91 B(+4.6%) |
| Mar 2005 | - | -$1.56 B(+143.7%) | -$3.74 B(+35.6%) |
| Dec 2004 | -$2.76 B(+3.3%) | -$641.00 M(-39.3%) | -$2.76 B(-36.6%) |
| Sept 2004 | - | -$1.06 B(+118.2%) | -$4.36 B(+39.1%) |
| June 2004 | - | -$484.00 M(-16.6%) | -$3.13 B(-0.2%) |
| Mar 2004 | - | -$580.00 M(-74.1%) | -$3.14 B(+17.3%) |
| Dec 2003 | -$2.67 B(-19.3%) | -$2.24 B(-1418.9%) | -$2.67 B(-7.1%) |
| Sept 2003 | - | $169.68 M(-134.7%) | -$2.88 B(+55.2%) |
| June 2003 | - | -$489.49 M(+321.3%) | -$1.85 B(-43.7%) |
| Mar 2003 | - | -$116.19 M(-95.2%) | -$3.30 B(-0.5%) |
| Dec 2002 | -$3.31 B(+71.2%) | -$2.44 B(-304.6%) | -$3.31 B(+160.4%) |
| Sept 2002 | - | $1.19 B(-161.9%) | -$1.27 B(-50.1%) |
| June 2002 | - | -$1.93 B(+1351.1%) | -$2.55 B(+34.1%) |
| Mar 2002 | - | -$133.00 M(-67.0%) | -$1.90 B(-1.8%) |
| Dec 2001 | -$1.94 B(+383.4%) | -$403.00 M(+391.5%) | -$1.94 B(+21.5%) |
| Sept 2001 | - | -$82.00 M(-93.6%) | -$1.59 B(+1.1%) |
| June 2001 | - | -$1.28 B(+665.9%) | -$1.58 B(+276.3%) |
| Mar 2001 | - | -$167.46 M(+174.9%) | -$418.93 M(+4.7%) |
| Dec 2000 | -$400.29 M(-75.8%) | -$60.91 M(-6.8%) | -$400.29 M(+17.9%) |
| Sept 2000 | - | -$65.34 M(-47.8%) | -$339.38 M(+23.8%) |
| June 2000 | - | -$125.23 M(-15.8%) | -$274.04 M(+84.2%) |
| Mar 2000 | - | -$148.81 M | -$148.81 M |
| Dec 1999 | -$1.65 B(+631.0%) | - | - |
| Dec 1998 | -$226.00 M(+327.2%) | - | - |
| Dec 1997 | -$52.90 M(-20.8%) | - | - |
| Dec 1996 | -$66.79 M(-190.0%) | - | - |
| Dec 1995 | $74.17 M(-109.2%) | - | - |
| Dec 1994 | -$805.15 M(-219.9%) | - | - |
| Dec 1993 | $671.56 M(+638.0%) | - | - |
| Dec 1992 | $91.00 M(-134.7%) | - | - |
| Dec 1991 | -$261.97 M(-52.8%) | - | - |
| Dec 1990 | -$555.53 M | - | - |
FAQ
- What is AstraZeneca annual cash flow from financing activities?
- What is the all time high annual CFF for AstraZeneca?
- What is AstraZeneca annual CFF year-on-year change?
- What is AstraZeneca quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for AstraZeneca?
- What is AstraZeneca quarterly CFF year-on-year change?
- What is AstraZeneca TTM cash flow from financing activities?
- What is the all time high TTM CFF for AstraZeneca?
- What is AstraZeneca TTM CFF year-on-year change?
What is AstraZeneca annual cash flow from financing activities?
The current annual CFF of AZN is -$6.57 B
What is the all time high annual CFF for AstraZeneca?
AstraZeneca all-time high annual cash flow from financing activities is $6.05 B
What is AstraZeneca annual CFF year-on-year change?
Over the past year, AZN annual cash flow from financing activities has changed by +$256.00 M (+3.75%)
What is AstraZeneca quarterly cash flow from financing activities?
The current quarterly CFF of AZN is -$4.13 B
What is the all time high quarterly CFF for AstraZeneca?
AstraZeneca all-time high quarterly cash flow from financing activities is $12.21 B
What is AstraZeneca quarterly CFF year-on-year change?
Over the past year, AZN quarterly cash flow from financing activities has changed by -$1.41 B (-51.54%)
What is AstraZeneca TTM cash flow from financing activities?
The current TTM CFF of AZN is -$3.62 B
What is the all time high TTM CFF for AstraZeneca?
AstraZeneca all-time high TTM cash flow from financing activities is $6.70 B
What is AstraZeneca TTM CFF year-on-year change?
Over the past year, AZN TTM cash flow from financing activities has changed by +$3.02 B (+45.49%)